572 related articles for article (PubMed ID: 29572094)
21. Antisense oligonucleotide treatment ameliorates alpha-1 antitrypsin-related liver disease in mice.
Guo S; Booten SL; Aghajan M; Hung G; Zhao C; Blomenkamp K; Gattis D; Watt A; Freier SM; Teckman JH; McCaleb ML; Monia BP
J Clin Invest; 2014 Jan; 124(1):251-61. PubMed ID: 24355919
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of inhaled α1-antitrypsin in patients with severe α1-antitrypsin deficiency and frequent exacerbations of COPD.
Stolk J; Tov N; Chapman KR; Fernandez P; MacNee W; Hopkinson NS; Piitulainen E; Seersholm N; Vogelmeier CF; Bals R; McElvaney G; Stockley RA
Eur Respir J; 2019 Nov; 54(5):. PubMed ID: 31467115
[TBL] [Abstract][Full Text] [Related]
23. Heteropolymerization of α-1-antitrypsin mutants in cell models mimicking heterozygosity.
Laffranchi M; Berardelli R; Ronzoni R; Lomas DA; Fra A
Hum Mol Genet; 2018 May; 27(10):1785-1793. PubMed ID: 29538751
[TBL] [Abstract][Full Text] [Related]
24. Knockdown of Z Mutant Alpha-1 Antitrypsin In Vivo Using Modified DNA Antisense Oligonucleotides.
Aghajan M; Guo S; Monia BP
Methods Mol Biol; 2017; 1639():127-138. PubMed ID: 28752452
[TBL] [Abstract][Full Text] [Related]
25. Intensive smoking diminishes the differences in quality of life and exacerbation frequency between the alpha-1-antitrypsin deficiency genotypes PiZZ and PiSZ.
Bernhard N; Lepper PM; Vogelmeier C; Seibert M; Wagenpfeil S; Bals R; Fähndrich S
Respir Med; 2017 Sep; 130():1-8. PubMed ID: 29206626
[TBL] [Abstract][Full Text] [Related]
26. Survival Advantage of Both Human Hepatocyte Xenografts and Genome-Edited Hepatocytes for Treatment of α-1 Antitrypsin Deficiency.
Borel F; Tang Q; Gernoux G; Greer C; Wang Z; Barzel A; Kay MA; Shultz LD; Greiner DL; Flotte TR; Brehm MA; Mueller C
Mol Ther; 2017 Nov; 25(11):2477-2489. PubMed ID: 29032169
[TBL] [Abstract][Full Text] [Related]
27. Cleaning up alpha-1 antitrypsin deficiency related liver disease.
Rademacher L; Fromme M; Strnad P
Curr Opin Gastroenterol; 2023 May; 39(3):163-168. PubMed ID: 37144533
[TBL] [Abstract][Full Text] [Related]
28. The effects of weekly augmentation therapy in patients with PiZZ α1-antitrypsin deficiency.
Schmid ST; Koepke J; Dresel M; Hattesohl A; Frenzel E; Perez J; Lomas DA; Miranda E; Greulich T; Noeske S; Wencker M; Teschler H; Vogelmeier C; Janciauskiene S; Koczulla AR
Int J Chron Obstruct Pulmon Dis; 2012; 7():687-96. PubMed ID: 23055718
[TBL] [Abstract][Full Text] [Related]
29. Increased outer arm and core fucose residues on the N-glycans of mutated alpha-1 antitrypsin protein from alpha-1 antitrypsin deficient individuals.
McCarthy C; Saldova R; O'Brien ME; Bergin DA; Carroll TP; Keenan J; Meleady P; Henry M; Clynes M; Rudd PM; Reeves EP; McElvaney NG
J Proteome Res; 2014 Feb; 13(2):596-605. PubMed ID: 24328305
[TBL] [Abstract][Full Text] [Related]
30. [Alpha-1 antitrypsin deficiency: cause and cofactor for liver disease].
Burbaum B; Fromme M; Strnad P
Dtsch Med Wochenschr; 2021 Jun; 146(11):714-718. PubMed ID: 34062584
[TBL] [Abstract][Full Text] [Related]
31. Exacerbations and duration of smoking abstinence are associated with the annual loss of FEV
Fähndrich S; Bernhard N; Lepper PM; Vogelmeier C; Seibert M; Wagenpfeil S; Bals R
Respir Med; 2017 Aug; 129():8-15. PubMed ID: 28732839
[TBL] [Abstract][Full Text] [Related]
32. Hereditary alpha-1-antitrypsin deficiency and its clinical consequences.
Fregonese L; Stolk J
Orphanet J Rare Dis; 2008 Jun; 3():16. PubMed ID: 18565211
[TBL] [Abstract][Full Text] [Related]
33. Genotyping diagnosis of alpha-1 antitrypsin deficiency in Saudi adults with liver cirrhosis.
Al-Jameil N; Hassan AA; Buhairan A; Hassanato R; Isac SR; Al-Otaiby M; Al-Maarik B; Al-Ajeyan I
Medicine (Baltimore); 2017 Feb; 96(6):e6071. PubMed ID: 28178162
[TBL] [Abstract][Full Text] [Related]
34. The Biological Effects of Double-Dose Alpha-1 Antitrypsin Augmentation Therapy. A Pilot Clinical Trial.
Campos MA; Geraghty P; Holt G; Mendes E; Newby PR; Ma S; Luna-Diaz LV; Turino GM; Stockley RA
Am J Respir Crit Care Med; 2019 Aug; 200(3):318-326. PubMed ID: 30965011
[No Abstract] [Full Text] [Related]
35. Liver organoids reproduce alpha-1 antitrypsin deficiency-related liver disease.
Gómez-Mariano G; Matamala N; Martínez S; Justo I; Marcacuzco A; Jimenez C; Monzón S; Cuesta I; Garfia C; Martínez MT; Huch M; Pérez de Castro I; Posada M; Janciauskiene S; Martínez-Delgado B
Hepatol Int; 2020 Jan; 14(1):127-137. PubMed ID: 31832977
[TBL] [Abstract][Full Text] [Related]
36. New Findings in PiZZ alpha1-antitrypsin deficiency-related panniculitis. Demonstration of skin polymers and high dosing requirements of intravenous augmentation therapy.
Gross B; Grebe M; Wencker M; Stoller JK; Bjursten LM; Janciauskiene S
Dermatology; 2009; 218(4):370-5. PubMed ID: 19218787
[TBL] [Abstract][Full Text] [Related]
37. Liver disease in alpha-1 antitrypsin deficiency: current understanding and future therapy.
Teckman JH
COPD; 2013 Mar; 10 Suppl 1():35-43. PubMed ID: 23527737
[TBL] [Abstract][Full Text] [Related]
38. Protein modeling to assess the pathogenicity of rare variants of SERPINA1 in patients suspected of having Alpha 1 Antitrypsin Deficiency.
Kueppers F; Andrake MD; Xu Q; Dunbrack RL; Kim J; Sanders CL
BMC Med Genet; 2019 Jul; 20(1):125. PubMed ID: 31307431
[TBL] [Abstract][Full Text] [Related]
39. Introducing standards of the best medical practice for patients with inherited alpha-1-antitrypsin deficiency in Central Eastern Europe.
Valiulis A; Utkus A; Stukas R; Valiulis A; Siderius L;
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2014; 35(1):107-14. PubMed ID: 24798601
[TBL] [Abstract][Full Text] [Related]
40. Bone marrow stem cell therapy partially ameliorates pathological consequences in livers of mice expressing mutant human α1-antitrypsin.
Baligar P; Kochat V; Arindkar SK; Equbal Z; Mukherjee S; Patel S; Nagarajan P; Mohanty S; Teckman JH; Mukhopadhyay A
Hepatology; 2017 Apr; 65(4):1319-1335. PubMed ID: 28056498
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
